Trial Profile
Prognostic impact of C-reactive protein kinetics for advanced renal cell carcinoma treated with sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 20 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.